03/13/2026
FPMA ADVOCACY WIN! 🎉
HB 567 / SB 1092 – Podiatric Medicine
The Florida Podiatric Medical Association (FPMA) is proud to announce a major advocacy victory during the 2026 Florida Legislative Session.
On March 10, 2026, as a direct result of FPMA’s advocacy efforts, HB 567 / SB 1092 successfully passed both chambers of the Florida Legislature and now moves to the Governor’s desk for signature.
This legislation delivers two important updates that impact podiatric physicians in Florida:
1️⃣ Aligns Continuing Education Requirements with Prescribing Authority
The bill updates Florida law so that the 2-hour continuing education requirement on safe and effective prescribing of controlled substances will apply only to podiatric physicians who are registered with the U.S. Drug Enforcement Administration (DEA) and authorized to prescribe controlled substances.
Podiatric physicians who do not prescribe controlled substances will no longer be required to complete this training as part of their biennial licensure renewal.
2️⃣ Establishes Legal Parameters for Cellular and Tissue-Based Products
The legislation also creates a framework allowing qualified podiatric physicians to perform procedures using certain cellular or tissue-based products under specific regulatory safeguards. The law outlines requirements for manufacturing standards, patient consent, advertising disclosures, and oversight to ensure transparency and patient protection.
These changes represent a significant step forward in supporting podiatric physicians while maintaining strong patient safety standards.
Learn more about FPMA’s advocacy work and legislative priorities:
Advocacy – https://www.fpma.com/advocacy.php
For questions regarding this legislation, FPMA members can contact: importantinfo@fpma.com
HB 567 General Bill by Chaney, Co-Sponsors: Bartleman, Berfield, Edmonds, Grow, Long, Nix, Jr., Porras, Salzman, ValdésSB1092 General Bill by Massullo, Jr.